Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTMXNASDAQ:NBTXNASDAQ:NRXPNASDAQ:PRQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$2.64+10.0%$1.33$0.40▼$2.82$212.84M2.112.17 million shs3.41 million shsNBTXNanobiotix$4.71+2.6%$3.57$2.76▼$6.00$222.00M0.3615,669 shs8,003 shsNRXPNRx Pharmaceuticals$3.27+11.2%$2.21$1.10▼$6.01$56.54M1.54406,011 shs402,162 shsPRQRProQR Therapeutics$1.91+6.7%$1.51$1.07▼$4.62$200.96M0.31639,611 shs329,821 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics0.00%+4.76%+141.10%+297.05%+58.08%NBTXNanobiotix0.00%+14.71%+38.12%+40.60%-26.64%NRXPNRx Pharmaceuticals0.00%+24.81%+59.51%+50.69%-8.15%PRQRProQR Therapeutics0.00%+13.69%+23.23%0.00%-4.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTMXCytomX Therapeutics4.4916 of 5 stars3.52.00.04.73.22.51.3NBTXNanobiotix1.0854 of 5 stars3.32.00.00.00.00.00.6NRXPNRx Pharmaceuticals2.4573 of 5 stars3.63.00.00.02.50.80.6PRQRProQR Therapeutics2.9055 of 5 stars4.63.00.00.03.30.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTMXCytomX Therapeutics 3.00Buy$5.33102.02% UpsideNBTXNanobiotix 2.50Moderate Buy$8.0069.85% UpsideNRXPNRx Pharmaceuticals 3.20Buy$28.50771.56% UpsidePRQRProQR Therapeutics 3.13Buy$8.00318.85% UpsideCurrent Analyst Ratings BreakdownLatest NRXP, CTMX, NBTX, and PRQR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.005/16/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.005/15/2025CTMXCytomX TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$2.50 ➝ $5.005/15/2025CTMXCytomX TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$5.00 ➝ $5.005/13/2025PRQRProQR TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $9.005/12/2025CTMXCytomX TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.00 ➝ $6.004/30/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.004/29/2025NRXPNRx PharmaceuticalsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $46.004/29/2025PRQRProQR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$8.004/29/2025PRQRProQR TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.004/14/2025CTMXCytomX TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$3.25 ➝ $2.50(Data available from 6/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTMXCytomX Therapeutics$147.56M1.44N/AN/A($0.71) per share-3.72NBTXNanobiotix-$11.61M-19.12N/AN/A($0.04) per share-117.75NRXPNRx PharmaceuticalsN/AN/AN/AN/A($1.38) per shareN/APRQRProQR Therapeutics$18.97M10.59N/AN/A$0.55 per share3.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTMXCytomX Therapeutics-$570K$0.4815.53N/AN/A10.96%-41.47%8.11%8/6/2025 (Estimated)NBTXNanobiotix-$42.97MN/A0.00N/AN/AN/AN/AN/AN/ANRXPNRx Pharmaceuticals-$30.15M-$2.01N/AN/AN/AN/AN/A-449.16%8/13/2025 (Estimated)PRQRProQR Therapeutics-$30.43M-$0.35N/AN/AN/A-134.31%-71.58%-19.70%8/4/2025 (Estimated)Latest NRXP, CTMX, NBTX, and PRQR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025NRXPNRx Pharmaceuticals-$0.40-$0.34+$0.06-$0.34$1.14 million$1.14 million5/12/2025Q1 2025CTMXCytomX Therapeutics$0.18$0.27+$0.09$0.27$35.42 million$50.92 million5/8/2025Q1 2025PRQRProQR Therapeutics-$0.09-$0.1082-$0.0182-$0.11$4.90 million$4.89 million3/14/2025Q4 2024NRXPNRx Pharmaceuticals-$0.20-$0.30-$0.10-$0.77N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTMXCytomX TherapeuticsN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTMXCytomX TherapeuticsN/A1.041.04NBTXNanobiotixN/A1.42N/ANRXPNRx PharmaceuticalsN/A0.200.20PRQRProQR TherapeuticsN/A2.332.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTMXCytomX Therapeutics67.77%NBTXNanobiotix38.81%NRXPNRx Pharmaceuticals4.27%PRQRProQR Therapeutics32.65%Insider OwnershipCompanyInsider OwnershipCTMXCytomX Therapeutics6.60%NBTXNanobiotix3.45%NRXPNRx Pharmaceuticals19.00%PRQRProQR Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTMXCytomX Therapeutics17080.62 million72.78 millionOptionableNBTXNanobiotix10047.13 million45.51 millionNot OptionableNRXPNRx Pharmaceuticals217.29 million12.72 millionOptionablePRQRProQR Therapeutics180105.21 million74.82 millionOptionableNRXP, CTMX, NBTX, and PRQR HeadlinesRecent News About These CompaniesTwo Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR)June 6 at 3:36 AM | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of "Buy" by AnalystsJune 5 at 1:33 AM | americanbankingnews.comProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of "Buy" by AnalystsJune 5 at 1:32 AM | marketbeat.comProQR Therapeutics Reports Q1 2025 Financial ResultsJune 3, 2025 | tipranks.comProQR Therapeutics (NASDAQ:PRQR) Short Interest Up 50.9% in MayJune 2, 2025 | marketbeat.comNorthern Trust Corp Has $1.11 Million Stock Holdings in ProQR Therapeutics (NASDAQ:PRQR)May 30, 2025 | marketbeat.comMillennium Management LLC Buys 2,683,351 Shares of ProQR Therapeutics (NASDAQ:PRQR)May 28, 2025 | marketbeat.comWoodline Partners LP Buys Shares of 3,557,001 ProQR Therapeutics (NASDAQ:PRQR)May 25, 2025 | marketbeat.comProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal yearMay 24, 2025 | investing.comPoint72 Asset Management L.P. Takes Position in ProQR Therapeutics (NASDAQ:PRQR)May 22, 2025 | marketbeat.comFY2025 EPS Forecast for ProQR Therapeutics Cut by AnalystMay 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $602,000 in ProQR Therapeutics (NASDAQ:PRQR)May 16, 2025 | marketbeat.comProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock NewsMay 13, 2025 | gurufocus.comProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES ConferencesMay 12, 2025 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from AnalystsMay 12, 2025 | marketbeat.comProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial PositionMay 10, 2025 | nasdaq.comProQR Therapeutics (NASDAQ:PRQR) Shares Acquired by DAFNA Capital Management LLCMay 10, 2025 | marketbeat.comProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial ResultsMay 10, 2025 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial ResultsMay 10, 2025 | finanznachrichten.deNew Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)May 10, 2025 | finance.yahoo.comProQR: Q1 Earnings SnapshotMay 10, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRXP, CTMX, NBTX, and PRQR Company DescriptionsCytomX Therapeutics NASDAQ:CTMX$2.64 +0.24 (+10.00%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$2.66 +0.01 (+0.57%) As of 06/6/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Nanobiotix NASDAQ:NBTX$4.70 +0.11 (+2.29%) As of 06/6/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.NRx Pharmaceuticals NASDAQ:NRXP$3.27 +0.33 (+11.22%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$3.32 +0.04 (+1.38%) As of 06/6/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.ProQR Therapeutics NASDAQ:PRQR$1.91 +0.12 (+6.70%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.92 +0.01 (+0.26%) As of 06/6/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later? MongoDB Affirms Outlook and Accelerates Stock Price Reversal Five Below Pops on Strong Earnings, But Rally May Stall Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
